Cargando…

Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale

Splicing of the human vascular endothelial growth factor-A (VEGF-A) gene has been reported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms. Corresponding VEGFxxxb isoforms have also been reported in rat and mouse. We examined VEGFxxxb expression in mouse fibrosarcoma cell li...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Sheila, Craze, Madeleine, Newton, Jillian, Fisher, Matthew, Shima, David T., Tozer, Gillian M., Kanthou, Chryso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342274/
https://www.ncbi.nlm.nih.gov/pubmed/22567098
http://dx.doi.org/10.1371/journal.pone.0035231
_version_ 1782231669985509376
author Harris, Sheila
Craze, Madeleine
Newton, Jillian
Fisher, Matthew
Shima, David T.
Tozer, Gillian M.
Kanthou, Chryso
author_facet Harris, Sheila
Craze, Madeleine
Newton, Jillian
Fisher, Matthew
Shima, David T.
Tozer, Gillian M.
Kanthou, Chryso
author_sort Harris, Sheila
collection PubMed
description Splicing of the human vascular endothelial growth factor-A (VEGF-A) gene has been reported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms. Corresponding VEGFxxxb isoforms have also been reported in rat and mouse. We examined VEGFxxxb expression in mouse fibrosarcoma cell lines expressing all or individual VEGF isoforms (VEGF120, 164 or 188), grown in vitro and in vivo, and compared results with those from normal mouse and human tissues. Importantly, genetic construction of VEGF164 and VEGF188 expressing fibrosarcomas, in which exon 7 is fused to the conventional exon 8, precludes VEGFxxxb splicing from occurring. Thus, these two fibrosarcoma cell lines provided endogenous negative controls. Using RT-PCR we show that primers designed to simultaneously amplify VEGFxxx and VEGFxxxb isoforms amplified only VEGFxxx variants in both species. Moreover, only VEGFxxx species were generated when mouse podocytes were treated with TGFβ-1, a reported activator of VEGFxxxb splice selection in human podocytes. A VEGF164/120 heteroduplex species was identified as a PCR artefact, specifically in mouse. VEGFxxxb isoform-specific PCR did amplify putative VEGFxxxb species in mouse and human tissues, but unexpectedly also in VEGF188 and VEGF164 fibrosarcoma cells and tumours, where splicing to produce true VEGFxxxb isoforms cannot occur. Moreover, these products were only consistently generated using reverse primers spanning more than 5 bases across the 8b/7 or 8b/5 splice junctions. Primer annealing to VEGFxxx transcripts and amplification of exon 8b primer ‘tails’ explained the artefactual generation of VEGFxxxb products, since the same products were generated when the PCR reactions were performed with cDNA from VEGF164/VEGF188 ‘knock-in’ vectors used in the generation of single VEGF isoform-expressing transgenic mice from which the fibrosarcoma lines were developed. Collectively, our results highlight important pitfalls in data interpretation associated with detecting VEGFxxxb isoforms using current methods, and demonstrate that anti-angiogenic isoforms are not commonly expressed in mouse or human tissues.
format Online
Article
Text
id pubmed-3342274
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33422742012-05-07 Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale Harris, Sheila Craze, Madeleine Newton, Jillian Fisher, Matthew Shima, David T. Tozer, Gillian M. Kanthou, Chryso PLoS One Research Article Splicing of the human vascular endothelial growth factor-A (VEGF-A) gene has been reported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms. Corresponding VEGFxxxb isoforms have also been reported in rat and mouse. We examined VEGFxxxb expression in mouse fibrosarcoma cell lines expressing all or individual VEGF isoforms (VEGF120, 164 or 188), grown in vitro and in vivo, and compared results with those from normal mouse and human tissues. Importantly, genetic construction of VEGF164 and VEGF188 expressing fibrosarcomas, in which exon 7 is fused to the conventional exon 8, precludes VEGFxxxb splicing from occurring. Thus, these two fibrosarcoma cell lines provided endogenous negative controls. Using RT-PCR we show that primers designed to simultaneously amplify VEGFxxx and VEGFxxxb isoforms amplified only VEGFxxx variants in both species. Moreover, only VEGFxxx species were generated when mouse podocytes were treated with TGFβ-1, a reported activator of VEGFxxxb splice selection in human podocytes. A VEGF164/120 heteroduplex species was identified as a PCR artefact, specifically in mouse. VEGFxxxb isoform-specific PCR did amplify putative VEGFxxxb species in mouse and human tissues, but unexpectedly also in VEGF188 and VEGF164 fibrosarcoma cells and tumours, where splicing to produce true VEGFxxxb isoforms cannot occur. Moreover, these products were only consistently generated using reverse primers spanning more than 5 bases across the 8b/7 or 8b/5 splice junctions. Primer annealing to VEGFxxx transcripts and amplification of exon 8b primer ‘tails’ explained the artefactual generation of VEGFxxxb products, since the same products were generated when the PCR reactions were performed with cDNA from VEGF164/VEGF188 ‘knock-in’ vectors used in the generation of single VEGF isoform-expressing transgenic mice from which the fibrosarcoma lines were developed. Collectively, our results highlight important pitfalls in data interpretation associated with detecting VEGFxxxb isoforms using current methods, and demonstrate that anti-angiogenic isoforms are not commonly expressed in mouse or human tissues. Public Library of Science 2012-05-02 /pmc/articles/PMC3342274/ /pubmed/22567098 http://dx.doi.org/10.1371/journal.pone.0035231 Text en Harris et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Harris, Sheila
Craze, Madeleine
Newton, Jillian
Fisher, Matthew
Shima, David T.
Tozer, Gillian M.
Kanthou, Chryso
Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
title Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
title_full Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
title_fullStr Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
title_full_unstemmed Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
title_short Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
title_sort do anti-angiogenic vegf (vegfxxxb) isoforms exist? a cautionary tale
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342274/
https://www.ncbi.nlm.nih.gov/pubmed/22567098
http://dx.doi.org/10.1371/journal.pone.0035231
work_keys_str_mv AT harrissheila doantiangiogenicvegfvegfxxxbisoformsexistacautionarytale
AT crazemadeleine doantiangiogenicvegfvegfxxxbisoformsexistacautionarytale
AT newtonjillian doantiangiogenicvegfvegfxxxbisoformsexistacautionarytale
AT fishermatthew doantiangiogenicvegfvegfxxxbisoformsexistacautionarytale
AT shimadavidt doantiangiogenicvegfvegfxxxbisoformsexistacautionarytale
AT tozergillianm doantiangiogenicvegfvegfxxxbisoformsexistacautionarytale
AT kanthouchryso doantiangiogenicvegfvegfxxxbisoformsexistacautionarytale